Ancillary Materials in Cell Therapy Manufacturing

Updated on Dec 2, 2025 | Published on Nov 30, 2025 Share

In cell and gene therapy manufacturing, understanding each raw material input is critical to patient safety and therapeutic success. Ancillary materials (AMs) are the reagents, buffers, and biologic process aids used during cell manipulation, purification, and expansion.

Although they do not remain in the final product, AM quality directly impacts consistency, safety, and regulatory approval. As manufacturing scales from discovery to commercialization, qualifying these materials appropriately can mean the difference between a smooth regulatory review and costly delays.

How Are Ancillary Materials Used in Cell Therapy?

From cell isolation to cytokine-driven activation, ancillary materials support nearly every stage of cell therapy manufacturing. These reagents come into direct contact with patient-derived cells, meaning any variability or impurity can impact product quality. Therefore, regulators such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require full control and documentation of all materials that may influence product and, ultimately, patient safety, even if they are removed before dosing.

Regulatory Expectations: Qualification and Risk Assessment

Qualifying ancillary materials is both a regulatory documentation requirement and a risk mitigation strategy for product development. The FDA and EMA expect therapy manufacturers to perform risk-based qualification for all raw and processed materials, balancing the level of control with the potential safety and quality impact of that material on the final product.

There are two key components to this process: material qualification and supplier qualification.

1. Material qualification ensures that the specific reagent or component meets defined quality, purity, safety, and performance criteria.
2. Supplier qualification evaluates the manufacturer’s ability to consistently meet those specifications through documented quality systems, process controls, and change management procedures.

A robust risk assessment categorizes AMs according to their likelihood of impacting the product. High-risk materials, such as those in direct contact with patient cells or derived from biological sources, require greater scrutiny. These additional measures may include supplier audits or additional in-house testing.

Partnering with a supplier that already operates under GMP and ISO-aligned quality systems and provides transparent regulatory documentation simplifies this process considerably. For example, Akadeum’s microbubble reagents are manufactured under GMP-controlled, validated conditions with complete traceability, supporting smooth integration into GMP workflows and regulatory submissions.

What Does GMP Mean at Akadeum?

Not all materials used in cell and gene therapy are created equal. The distinction between RUO and GMP-grade defines regulatory compliance and, by extension, how easily a therapy can move from research to regulatory approval. Let’s compare the three tiers:

• Research Use Only (RUO). RUO materials are ideal for exploratory studies. They tend to be more affordable but are not manufactured under formal quality systems, and therefore lack the documentation needed for regulatory filings.
• Good Manufacturing Practice (GMP). GMP-grade materials comply with 21 CFR parts 210, 211, 820, and 11, with defined quality systems, batch records, raw material traceability, and release testing. Akadeum takes a risk-based approach, adhering to ISO 14971 Risk Management. GMP-grade materials are typically suitable for many clinical applications but may not fully address the specialized requirements of ancillary materials used in cell and gene therapy.
• Akadeum’s GMP Kits build on GMP compliance by adhering to ancillary material–specific standards, including ISO 20399, ISO 10993, and USP <1043>. These standards cover extractables and toxicology, biocompatibility, and adventitious agents (viral) testing. Akadeum’s GMP Kits are also validated and fully documented in a Drug Master File (DMF) to support Investigational New Drug (IND) and Biologics License Application (BLA) submissions, minimizing requalification and de-risking tech transfer.

Choosing Ancillary Materials with an Eye Toward Regulatory Success

Selecting the right ancillary materials is a decision that involves both technical and regulatory considerations. Beyond cost and performance, each reagent must be evaluated for its fit within a compliant, scalable, and well-documented process. Here are the core factors to consider:

1. Supplier qualification. Does the supplier operate under an ISO-aligned or GMP-compliant quality management system? A formal quality system ensures the manufacturer follows defined procedures, maintains batch records, and documents change control—all critical for regulatory audits.
2. Documentation and traceability. Each lot should be accompanied by a Certificate of Analysis (CoA), Safety Data Sheet (SDS), and Certificates of Origin (CoO, when applicable). For cell therapy manufacturers, these records form part of the Chemistry Manufacturing, and Controls (CMC) section of an IND submission.
3. Change control practices. Even minor formulation or process changes can impact product comparability. Confirm that your supplier has a clear notification system for changes and that any updates are reviewed for risk before implementation.
4. Performance validation. Understand if the material has undergone verification and validation as part of the product development process. For example, reagents validated in both open and closed systems provide more confidence for their use in early research and streamlined transfer to MSAT groups through to commercialization.
5. Scalability and supply continuity. Early-stage developers should confirm that their chosen materials can be supplied consistently at larger volumes. Sudden supplier changes at later stages can trigger requalification requirements, leading to costly production interruptions.

Akadeum’s microbubble reagents meet these expectations: manufactured under GMP and ISO-aligned systems, fully documented, and validated for research and GMP workflows.

Frequently Asked Questions

How are ancillary materials qualified for use in cell and gene therapy?
Qualification follows a risk-based assessment of both the material and its supplier, verifying the material’s origin, sterility, adventitious (viral) agent and endotoxin testing, as well as documentation and quality systems such as ISO 13485 or GMP. The level of diligence depends on the material’s contact with the product and the duration of that contact, as well as its potential safety impact.

What’s the difference between RUO, GMP-grade, and Clinical-Ready ancillary materials?
RUO materials are for early research and lack documentation for regulatory filings. GMP-grade materials meet FDA requirements under 21 CFR 210, 211, 820, and 11 but may not address ancillary-material–specific risks. It’s important to ensure materials meet ISO 20399, ISO 10993, and USP <1043> standards tailored to cell and gene therapy manufacturing.

Why do regulators care about ancillary materials if they aren’t part of the final product?
Regulators require traceability and control of all materials that come into contact with a patient’s cells during the production of the therapeutic, as these factors influence product quality and potential patient safety. Even though ancillary materials are removed before therapy administration, they still come into contact with patient-derived cells. Any impurity or inconsistency can impact product safety, potency, or purity.

What documentation should accompany qualified ancillary materials?
Each lot should include a Certificate of Analysis (CoA), a Certificate of Origin (CoO, when applicable), a protocol for enumeration of residuals,  and a Safety Data Sheet (SDS), along with Quality Agreements that outline change-control procedures and product specifications. These records support the Chemistry Manufacturing, and Controls (CMC) section of regulatory submissions.

Can Akadeum’s reagents be used in GMP manufacturing workflows?
Yes. Akadeum’s microbubble reagents are manufactured under GMP and ISO 13485-aligned quality system, meeting GMP requirements under 21 CFR 820, 211, 210, and 11, and complying with ISO 20399, ISO 10993, and USP <1043> for ancillary materials—ensuring regulatory confidence during scale-up and validation. Akadeum is also aligned with ISO 14971 Application of Risk Management to Medical Devices.

Building Quality and Compliance from the Start

Ancillary materials may not remain in the final product, but their quality underpins every stage of therapy manufacturing. Using Akadeum’s qualified, GMP ancillary material reagents safeguards timelines, delivering performance, scalability, and regulatory confidence from research to commercialization.

→ Explore Akadeum’s GMP Cell Separation Kits and Regulatory Support